Following IBMTR model may make CAR-T therapies affordable, says oncologist and data specialist

1 September 2017

News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy of a question that has been hanging over these individually-tailored cancer treatments as they have edged closer to market – how on earth are health systems going to afford them?

First came US biotech giant Gilead Sciences’ (Nasdaq: GILD) $11.9 billion takeover of Kite Pharma (Nasdaq: KITE), one of the early front-runners in the CAR-T field with its axicabtagene ciloleucel (axi-cel) for refractory aggressive non-Hodgkin lymphoma.

"I think the government is going to almost insist that companies track their outcomes because otherwise if you record ones and twos, you'll never know where the therapy worked"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK